Andrew Raubitschek

11.6k citations

157 papers · 9.1k indexed · 2 hit papers · h-index 53

Radiology, Nuclear Medicine and Imaging top 0.1%
- Radiopharmaceutical Chemistry and Applications 80
- Monoclonal and Polyclonal Antibodies Research 63
- Medical Imaging Techniques and Applications 21
Oncology top 0.5%
- CAR-T cell therapy research 27
- HER2/EGFR in Cancer Research 17
Immunology top 1%
- Immune Cell Function and Interaction 16
- Immunotherapy and Immune Responses 15
Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 38
Genetics top 2%

Co-authors: John E. Shively Stephen J. Forman Anna M. Wu Lawrence E. Williams Michael C. Jensen David Colcher Paul J. Yazaki Jeffrey Y.C. Wong
Cited by: Radiology, Nuclear Medicine and Imaging Oncology Immunology
Partner nations: United States Slovakia Sweden

In The Last Decade

Andrew Raubitschek

153 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2012 CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
2008 Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

Peers

Countries citing papers authored by Andrew Raubitschek

Since Specialization

Citations

This map shows the geographic impact of Andrew Raubitschek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Raubitschek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Raubitschek more than expected).

Fields of papers citing papers by Andrew Raubitschek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Raubitschek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Raubitschek. The network helps show where Andrew Raubitschek may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew Raubitschek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Raubitschek Line = papers co-authored together Andrew Raubitschek links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma Benjamin Cahan,Lucille Leong,Lawrence D. Wagman,David Yamauchi,Stephen Shibata,Sharon Wilzcynski,Lawrence E. Williams,Paul J. Yazaki,David Colcher,Paul Frankel,Anna M. Wu,Andrew Raubitschek,John E. Shively,Jeffrey Y.C. Wong	2017	11
2	Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101 Thomas S.C. Ng,David Wert,Hargun Sohi,Daniele Procissi,David Colcher,Andrew Raubitschek,Russell E. Jacobs	2013	9
3	Intracellular processing of immunostimulatory CpG–siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape Sergey Nechaev,Chan Gao,Dayson Moreira,Piotr Swiderski,Agnieszka Jóźwiak,Claudia Kowolik,Jiehua Zhou,Brian Armstrong,Andrew Raubitschek,John J. Rossi,Marcin Kortylewski	2013	42
4	Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice Haitao Fan,Ian Zhang,Xuebo Chen,Leying Zhang,Huaqing Wang,Anna Da Fonseca,Edwin R. Manuel,Don J. Diamond,Andrew Raubitschek,Behnam Badie	2012	48
5	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsbreakdown → Brian G. Till,Michael C. Jensen,Jinjuan Wang,Xiaojun Qian,Ajay K. Gopal,David G. Maloney,Catherine Lindgren,Yukang Lin,John M. Pagel,Lihua E. Budde,Andrew Raubitschek,Stephen J. Forman,Philip D. Greenberg,Stanley R. Riddell,Oliver W. Press	2012	431
6	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance Paul J. Yazaki,B. Lee,Divya Channappa,Chi Wai Cheung,Desiree Crow,Junie Chea,Erasmus Poku,Liang Li,Jan Terje Andersen,Inger Sandlie,Kelly Davis Orcutt,K. Dane Wittrup,John E. Shively,Andrew Raubitschek,David Colcher	2012	29
7	Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation–Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma Amrita Krishnan,Joycelynne Palmer,Ni‐Chun Tsai,Jennifer Simpson,Auayporn Nademanee,Andrew Raubitschek,Sandra H. Thomas,Stephen J. Forman	2011	29
8	A Pretherapy Biodistribution and Dosimetry Study of Indium-111-Radiolabeled Trastuzumab in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Jeffrey Y.C. Wong,Andrew Raubitschek,Dave Yamauchi,Lawrence E. Williams,Anna M. Wu,Paul J. Yazaki,John E. Shively,David Colcher,George Somlo	2010	22
9	ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies) Tove Olafsen,Shannon J. Sirk,David J. Betting,Vania Kenanova,Karl B. Bauer,Waldemar Ladno,Andrew Raubitschek,John M. Timmerman,Anna M. Wu	2010	35
10	Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane Scott E. James,Philip D. Greenberg,Michael C. Jensen,Yukang Lin,Jinjuan Wang,Brian G. Till,Andrew Raubitschek,Stephen J. Forman,Oliver W. Press	2008	196
11	Quantitative Serial Imaging of an ¹²⁴ I Anti-CEA Monoclonal Antibody in Tumor-Bearing Mice James R. Bading,Magnus Hörling,Lawrence E. Williams,David Colcher,Andrew Raubitschek,Sven‐Erik Strand	2008	14
12	Intratumoral immunocytokine treatment results in enhanced antitumor effects Erik E. Johnson,Hillary D. Lum,Alexander L. Rakhmilevich,Brian E. Schmidt,Meghan Jo'An Furlong,Ilia N. Buhtoiarov,Jacquelyn A. Hank,Andrew Raubitschek,David Colcher,Ralph A. Reisfeld,Stephen D. Gillies,Paul M. Sondel	2008	47
13	Combining Adoptive Cellular and Immunocytokine Therapies to Improve Treatment of B-Lineage Malignancy Harjeet Singh,Lisa Marie Serrano,Timothy Pfeiffer,Simon Olivares,George McNamara,David Smith,Zaid Al‐Kadhimi,Stephen J. Forman,Stephen D. Gillies,Michael C. Jensen,David Colcher,Andrew Raubitschek,Laurence J.N. Cooper	2007	31
14	Combined Radioimmunotherapy and Chemotherapy of Breast Tumors with Y-90-Labeled Anti-Her2 and Anti-CEA Antibodies with Taxol Desiree Crow,Lawrence E. Williams,David Colcher,Jeffrey Y.C. Wong,Andrew Raubitschek,John E. Shively	2005	26
15	Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing Christine E. Brown,Christine L. Wright,Araceli Naranjo,Reena Vishwanath,Wen-Chung Chang,Simon Olivares,Jamie R. Wagner,Laura A. Bruins,Andrew Raubitschek,Laurence J.N. Cooper,Michael C. Jensen	2005	59
16	Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy Jeffrey Y.C. Wong,Jianyi Wang,An Liu,Tamara Odom‐Maryon,John E. Shively,Andrew Raubitschek,Lawrence E. Williams	2000	8
17	Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma Gregory A. Wiseman,Christine A. White,Michael Stabin,William L. Dunn,William D. Erwin,Magnus Dahlbom,Andrew Raubitschek,Kastytis C. Karvelis,Timothy E. Schultheiss,Thomas E. Witzig,Richard E. Bélanger,Stewart Spies,Daniel Silverman,Judy Berlfein,Eric Ding,Antonio J Grillo-López	2000	189
18	A Shielded, Automated Injector for Energetic Beta-Emitting Radionuclides Lawrence E. Williams,Lupe M. Ettinger,Enrique Cofresi,Andrew Raubitschek,Jeffrey Y.C. Wong	1995	1
19	Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies Lawrence E. Williams,An Liu,Anna M. Wu,Tamara Odom‐Maryon,Akiko Chai,Andrew Raubitschek,Jeffrey Y.C. Wong	1995	16
20	The never-ending controversies in Hodgkin's disease Andrew Raubitschek,Eli Glatstein	1989	16

About Andrew Raubitschek

Andrew Raubitschek is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pathology and Forensic Medicine, having authored 157 papers that have together received 9.1k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (80 papers), Monoclonal and Polyclonal Antibodies Research (63 papers), Lymphoma Diagnosis and Treatment (38 papers), CAR-T cell therapy research (27 papers), Medical Imaging Techniques and Applications (21 papers), HER2/EGFR in Cancer Research (17 papers), Immune Cell Function and Interaction (16 papers) and Immunotherapy and Immune Responses (15 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (4.3k citations), Oncology (4.3k citations) and Immunology (2.2k citations). Andrew Raubitschek has collaborated with scholars based in United States, Slovakia and Sweden. Frequent co-authors include John E. Shively, Stephen J. Forman, Anna M. Wu, Lawrence E. Williams, Michael C. Jensen, David Colcher, Paul J. Yazaki, Jeffrey Y.C. Wong, Oliver W. Press and Philip D. Greenberg.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact